Evoke Wealth’s GSK GSK Stock Holding History

Evoke Wealth’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,962	Closed	-$220K	–	268
2026 Q1	$220K	Sell	3,962 -433	-10%	-$23.5K	﹤0.01%	634
2025 Q4	$217K	Buy	+4,395	New	+$205K	﹤0.01%	611
2022 Q4	–	Sell	-584	Closed	-$17K	–	694
2022 Q3	$17K	Hold	584	–	–	﹤0.01%	665
2022 Q2	$32K	Hold	584	–	–	﹤0.01%	581
2022 Q1	$32K	Hold	584	–	–	﹤0.01%	580
2021 Q4	$33K	Hold	584	–	–	﹤0.01%	592
2021 Q3	$28K	Hold	584	–	–	﹤0.01%	581
2021 Q2	$29K	Hold	584	–	–	﹤0.01%	585
2021 Q1	$26K	Buy	584 +353	+153%	+$16K	﹤0.01%	542
2020 Q4	$11K	Hold	231	–	–	﹤0.01%	573
2020 Q3	$11K	Buy	231 +216	+1,440%	+$10.8K	﹤0.01%	547
2020 Q2	$1K	Buy	15 +8	+114%	+$410	﹤0.01%	971
2020 Q1	$363	Sell	7 -2,938	-100%	-$157K	﹤0.01%	1048
2019 Q4	$177K	Buy	2,945 +4	+0.1%	+$222	0.02%	241
2019 Q3	$159K	Buy	+2,941	New	+$151K	0.02%	299

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Evoke Wealth's GSK Position: Q2 2026 in Review

Evoke Wealth sold out of GSK (GSK) in Q2 2026, closing a stake of 3,962 shares — an estimated $220K sold.

Evoke Wealth first reported a position in GSK in Q3 2019 and held it in 15 quarters. The position peaked at $220K in Q1 2026. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Evoke Wealth reported no remaining GSK position as of Q2 2026 after selling out during the quarter.
Evoke Wealth sold 3,962 GSK shares in Q2 2026, an estimated $220K.
Evoke Wealth first reported a position in GSK in Q3 2019 and held it in 15 quarters.
Evoke Wealth's GSK position peaked at $220K in Q1 2026.
1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Evoke Wealth's 13F filing for Q2 2026, filed 10 Aug 2026.